P&G reaffirms second quarter outlook
This article was originally published in The Rose Sheet
Executive Summary
Fiscal 2002 (ending June 30) sales and earnings expected to be in line with earlier guidance, P&G predicts Dec. 11. Earnings per share likely will exceed last year's levels, but will not reach company's long-term double-digit goal, while sales gains, excluding currency, are expected to be higher than the prior year, but will not reach long-term goal of 4%-6%, P&G says. For the second quarter, both sales and volume are expected to increase at upper end of previous guidance of low single digit growth (1% to 3%), firm adds. Estimates include impact on results from Clairol acquisition. Announcement sparked interest on Wall Street with stock advancing 4.2% to reach 52-week high of 79.9...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.